Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

April 30, 2016

Conditions

Endometriosis

Interventions

DRUG

BAY1128688

Part A: Single dose and multiple dose for 14 days (postmenopausal women)

DRUG

Placebo

Part A: Single dose and multiple dose for 14 days (postmenopausal women)

DRUG

BAY1128688

Part B: Multiple dose for 28 days (premenopausal women)

Trial Locations (3)

Berlin

Berlin

Neu-Ulm